836 related articles for article (PubMed ID: 21362200)
1. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
2. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
Miller TW; Hennessy BT; González-Angulo AM; Fox EM; Mills GB; Chen H; Higham C; García-Echeverría C; Shyr Y; Arteaga CL
J Clin Invest; 2010 Jul; 120(7):2406-13. PubMed ID: 20530877
[TBL] [Abstract][Full Text] [Related]
3. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Beeram M; Tan QT; Tekmal RR; Russell D; Middleton A; DeGraffenried LA
Ann Oncol; 2007 Aug; 18(8):1323-8. PubMed ID: 17693645
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.
Johnston SR; Martin LA; Head J; Smith I; Dowsett M
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):173-81. PubMed ID: 15996863
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
Crowder RJ; Phommaly C; Tao Y; Hoog J; Luo J; Perou CM; Parker JS; Miller MA; Huntsman DG; Lin L; Snider J; Davies SR; Olson JA; Watson MA; Saporita A; Weber JD; Ellis MJ
Cancer Res; 2009 May; 69(9):3955-62. PubMed ID: 19366795
[TBL] [Abstract][Full Text] [Related]
6. Mouse ER+/PIK3CA
Stratikopoulos EE; Kiess N; Szabolcs M; Pegno S; Kakit C; Wu X; Poulikakos PI; Cheung P; Schmidt H; Parsons R
Oncogene; 2019 Jan; 38(1):47-59. PubMed ID: 30076411
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
[TBL] [Abstract][Full Text] [Related]
8. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
[TBL] [Abstract][Full Text] [Related]
9. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
Brufsky AM
Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
[TBL] [Abstract][Full Text] [Related]
10. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.
Brachmann SM; Hofmann I; Schnell C; Fritsch C; Wee S; Lane H; Wang S; Garcia-Echeverria C; Maira SM
Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22299-304. PubMed ID: 20007781
[TBL] [Abstract][Full Text] [Related]
11. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Fox EM; Miller TW; Balko JM; Kuba MG; Sánchez V; Smith RA; Liu S; González-Angulo AM; Mills GB; Ye F; Shyr Y; Manning HC; Buck E; Arteaga CL
Cancer Res; 2011 Nov; 71(21):6773-84. PubMed ID: 21908557
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
Loi S; Haibe-Kains B; Majjaj S; Lallemand F; Durbecq V; Larsimont D; Gonzalez-Angulo AM; Pusztai L; Symmans WF; Bardelli A; Ellis P; Tutt AN; Gillett CE; Hennessy BT; Mills GB; Phillips WA; Piccart MJ; Speed TP; McArthur GA; Sotiriou C
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10208-13. PubMed ID: 20479250
[TBL] [Abstract][Full Text] [Related]
13. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Weigelt B; Warne PH; Downward J
Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
16. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
[TBL] [Abstract][Full Text] [Related]
17. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
18. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO; Spring LM; Bardia A; Wander SA
Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
[TBL] [Abstract][Full Text] [Related]
19. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
Jacquemetton J; Kassem L; Poulard C; Dahmani A; De Plater L; Montaudon E; Sourd L; Morisset L; El Botty R; Chateau-Joubert S; Vacher S; Bièche I; Treilleux I; Trédan O; Marangoni E; Le Romancer M
Breast Cancer Res; 2021 May; 23(1):57. PubMed ID: 34020697
[TBL] [Abstract][Full Text] [Related]
20. Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.
Patani N; Dunbier AK; Anderson H; Ghazoui Z; Ribas R; Anderson E; Gao Q; A'hern R; Mackay A; Lindemann J; Wellings R; Walker J; Kuter I; Martin LA; Dowsett M
Clin Cancer Res; 2014 Aug; 20(15):3962-73. PubMed ID: 24916694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]